Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials

Statistics in Medicine

Volumn 32, Issue 6, 2013, Pages 914-930

  Donegan, Sarah ^a   Williamson, Paula ^a   D'Alessandro, Umberto ^b   Garner, Paul ^c   Smith, Catrin Tudur ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Consistency; Individual patient data; Mixed treatment comparison; Multiple treatments meta analysis; Network meta analysis; Similarity

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; AMODIAQUINE PLUS PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRIMETHAMINE PLUS SULFADOXINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; GOLD STANDARD; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; META ANALYSIS; METHODOLOGY; MIXED TREATMENT COMPARISON; OUTCOME ASSESSMENT; PATIENT CODING; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REGRESSION COEFFICIENT; SCHOOL CHILD; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ARTEMISININS; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84873978476     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5584     Document Type: Article

References (68)

1. Clarke MJ, Stewart LA. Meta-analyses using individual patient data. Journal of Evaluation in Clinical Practice 1997; 3(3):207-212. DOI: 10.1046/j.1365-2753.1997.00005.x.
2. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. British Medical Journal 2010; 340:c221. DOI: 10.1136/bmj.c221.
3. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. Journal of Clinical Epidemiology 2002; 55(1):86-94. DOI: 10.1016/S0895-4356(01)00414-0.
4. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Statistics in Medicine 2002; 21(3):371-387. DOI: 10.1002/sim.1023.
5. Simmonds MC, Higgins JPT. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Statistics in Medicine 2007; 26(15):2982-2999. DOI: 10.1002/sim.2768.
6. Tudur Smith C, Williamson PR, Marson AG. An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. Journal of Evaluation in Clinical Practice 2005; 11(5):468-478. DOI: 10.1111/j.1365-2753.2005.00559.x.
7. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. Journal of Clinical Epidemiology 2004; 57(7):683-697. DOI: 10.1016/j.jclinepi.2003.12.001.
8. Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. Journal of Clinical Epidemiology 2007; 60(5):431-439. DOI: 10.1016/j.jclinepi.2006.09.009.
9. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, Boutitie F. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Statistics in Medicine 2008; 27(11):1870-1893. DOI: 10.1002/sim.3165.
10. Sutton AJ, Kendrick D, Coupland CAC. Meta-analysis of individual- and aggregate-level data. Statistics in Medicine 2008; 27(5):651-669, available at 10.1002/sim.2916.
11. Lu G, Ades A. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006; 101(474):447-459. DOI: 10.1198/016214505000001302.
12. Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; 23(20):3105-3124. DOI: 10.1002/sim.1875.
13. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002; 21(16):2313-2324. DOI: 10.1002/sim.1201.
14. Salanti G, Higgins J, Ades A, Ioannidis J. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008; 17(3):279-301. DOI: 10.1177/0962280207080643.
15. Higgins J, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 1996; 15(24):2733-2749. DOI: 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0.
16. Bucher H, Guyatt G, Griffith L, Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997; 50(6):683-691. DOI: 10.1016/S0895-4356(97)00049-8.
17. Glenny A, Altman D, Song F, Sakarovitch C, Deeks J, D'Amico R, Bradburn M, Eastwood A. Indirect comparisons of competing interventions. Health Technology Assessment 2005; 9(26):1-148.
18. Salanti G, Kavvoura F, Ioannidis J. Exploring the geometry of treatment networks. Annals of Internal Medicine 2008; 148(7):544-553.
19. Cooper N, Sutton A, Morris D, Ades A, Welton N. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Statistics in Medicine 2009; 28(14):1861-1881. DOI: 10.1002/sim.3594.
20. Tudur Smith C, Marson A, Chadwick D, Williamson P. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007; 8:34. DOI: 10.1186/1745-6215-8-34.
21. Salanti G, Marinho V, Higgins JPT. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Journal of Clinical Epidemiology 2009; 62(8):857-864. DOI: 10.1016/j.jclinepi.2008.10.001.
22. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine 2007; 26(6):1237-1254. DOI: 10.1002/sim.2624.
23. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials, 2011. (Available from: http://www.nicedsu.org.uk [Accessed on 9 June 2011]).
24. Riley RD, Steyerberg EW. Meta-analysis of a binary outcome using individual participant data and aggregate data. Research Synthesis Methods 2010; 1(1):2-19. DOI: 10.1002/jrsm.4.
25. Dias S, Welton NJ, Marinho VCC, Salanti G, Higgins JPT, Ades AE. Estimation and adjustment of bias in randomized evidence by using mixed treatment comparison meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2010; 173(3):613-629. DOI: 10.1111/j.1467-985X.2010.00639.x.
26. Woods B, Hawkins N, Scott D. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Medical Research Methodology 2010; 10:54. DOI: 10.1186/1471-2288-10-54.
27. Govan L, Ades AE, Weir CJ, Welton NJ, Langhorne P. Controlling ecological bias in evidence synthesis of trials reporting on collapsed and overlapping covariate categories. Statistics in Medicine 2010; 29(12):1340-1356. DOI: 10.1002/sim.3869.
28. Ades AE, Mavranezouli I, Dias S, Welton NJ, Whittington C, Kendall T. Network meta-analysis with competing risk outcomes. Value in Health 2010; 13(8):976-983. DOI: 10.1111/j.1524-4733.2010.00784.x.
29. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010; 29(7-8):932-944. DOI: 10.1002/sim.3767.
30. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Wiley: Chichester, 2002.
31. Jansen J. Network meta-analysis of survival data with fractional polynomials. BMC Medical Research Methodology 2011; 11(1):61. DOI: 10.1186/1471-2288-11-61.
32. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Guobing L, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 2011. (Available from: http://www.nicedsu.org.uk [Accessed on 9 June 2011]).
33. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2009(3). Art. No.: CD007483. DOI: 10.1002/14651858. CD007483.pub2.
34. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clinical Trials 2006; 1(1):e7. DOI: 10.1371/journal.pctr.0010007.
35. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100(12):1105-1111. DOI: 10.1016/j.trstmh.2006.01.001.
36. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malaria Journal 2008; 7:237. DOI: 10.1186/1475-2875-7-237.
37. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clinical Infectious Diseases 2007; 45(11):1453-1461. DOI: 10.1086/522985.
38. Adjei GO, Kurtzhals JAL, Rodrigues OP, Alifrangis M, Hoegberg LCG, Kitcher ED, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malaria Journal 2008; 7:127. DOI: 10.1186/1475-2875-7-127.
39. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Tropical Medicine and International Health 2008; 13(5):635-643. DOI: 10.1111/j.1365-3156.2008.02043.x.
40. Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, et al. High efficacy of two artemisinin-based combinations (artesunate+amodiaquine and artemether+lumefantrine) in Caala, Central Angola. American Journal of Tropical Medicine and Hygiene 2006; 75(1):143-145.
41. Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H, et al. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malaria Journal 2008; 7:261. DOI: 10.1186/1475-2875-7-261.
42. Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5years in Ghana. Acta Tropica 2005; 95(3):194-203. DOI: 10.1016/j.actatropica.2005.06.018.
43. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clinical Infectious Diseases 2005; 41(8):1079-1086. DOI: 10.1086/444460.
44. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, et al. An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS ONE 2008; 3(6):e2530. DOI: 10.1371/journal.pone.0002530.
45. Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malaria Journal 2007; 6:80. DOI: 10.1186/1475-2875-6-80.
46. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. The Journal of the American Medical Association 2007; 297(20):2210-2219. DOI: 10.1001/jama.297.20.2210.
47. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365(9469):1474-1480. DOI: 10.1016/S0140-6736(05)66417-3.
48. van den Broek I, Kitz C, Al Attas S, Libama F, Balasegaram M, Guthmann JP. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malaria Journal 2006; 5:113. DOI: 10.1186/1475-2875-5-113.
49. Menard D, Andrianina NN, Ramiandrasoa Z, Randriamanantena A, Rasoarilalao N, Jahevitra M, et al. Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar. Malaria Journal 2007; 6:65. DOI: 10.1186/1475-2875-6-65.
50. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet 2004; 364(9449):1950-1957. DOI: 10.1016/S0140-6736(04)17478-3.
51. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Medicine 2005; 2(7):e190. DOI: 10.1371/journal.pmed.0020190.
52. Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, et al. Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. Malaria Journal 2009; 8:5. DOI: 10.1186/1475-2875-8-5.
53. Bonnet M, Roper C, Felix M, Coulibaly L, Kankolongo GM, Guthmann JP. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zerekore. Malaria Journal 2007; 6:54. DOI: 10.1186/1475-2875-6-54.
54. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. American Journal of Tropical Medicine and Hygiene 2008; 78(3):455-461.
55. Guthmann JP, Ampuero J, Fortes F, van Overmeir C, Gaboulaud V, Tobback S, et al. Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine+artesunate and sulfadoxine-pyrimethamine+artesunate in Huambo and Bie provinces, central Angola. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005; 99(7):485-492. DOI: 10.1016/j.trstmh.2004.11.010.
56. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, et al. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005; 99(7):548-554. DOI: 10.1016/j.trstmh.2004.10.003.
57. Swarthout TD, van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C. Artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. Tropical Medicine and International Health 2006; 11(10):1503-1511. DOI: 10.1111/j.1365-3156.2006.01710.x.
58. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, et al. A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. American Journal of Tropical Medicine and Hygiene 2008; 79(5):655-661.
59. Fanello CI, Karema C, van Doren W, Van Overmeir C, Ngamije D, D'Alessandro U. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007; 101(4):344-350. DOI: 10.1016/j.trstmh.2006.06.010.
60. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369(9560):491-498. DOI: 10.1016/S0140-6736(07)60236-0.
61. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. Journal of Infectious Diseases 2006; 193(8):1151-1159. DOI: 10.1086/503051.
62. Mukhtar EA, Gadalla NB, El-Zaki SE, Mukhtar I, Mansour FA, Babiker A, et al. A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan. Malaria Journal 2007; 6:92. DOI: 10.1186/1475-2875-6-92.
63. The Four Artemisinin-Based Combinations Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Medicine 2011; 8(11):e1001119. DOI: 10.1371/journal.pmed.1001119.
64. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10:325-337.
65. Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. Journal of Statistical Software 2005; 12(3):1-16.
66. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
67. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2002; 64(4):583-639. DOI: 10.1111/1467-9868.00353.
68. Lu G, Ades A. Modeling between-trial variance structure in mixed treatment comparisons. Biostatistics 2009; 10(4):792-805. DOI: 10.1093/biostatistics/kxp032.